Monitoring of Regional Lung Ventilation by Chest Electrical Impedance in the Course of Extubation
Launched by BIOSERENITY · Nov 26, 2019
Trial Information
Current as of June 26, 2025
Unknown status
Keywords
ClinConnect Summary
The aim is to follow the patients after extubation for the lung description.
EIT exam is performed before extubation, during follow-up visits and 48H after extubation
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age\> 65 years
- • 2. Invasive mechanical ventilation time greater than 48 hours
- • 3. known or suspected Chronic obstructive pulmonary disease
- • 4. Known or suspected heart failure
- • 5. Success in the spontaneous ventilation and extubation test scheduled by the doctor in charge
- • 6. Patient or trusted person who has been informed of the study and has consented to participate
- Exclusion Criteria:
- • 1. Pregnant women, minor patients
- • 2. Patients under extracorporeal circulatory assistance (ECMO)
- • 3. Refusal of the patient
- 4. Contraindications to the realization of the phrenic nerve stimulation technique:
- • Pacemaker, implantable cardiac defibrillator and other pacemakers
- • Spinal implants, thoracic drains ...
- • Copper allergy
- • Epileptic patients
- • 5. Patients performing uncontrolled body movements
- 6. Contraindications to the realization of the technique of Electrical Imaging Tomography:
- • Breast circumference not between 70 cm and 150 cm.
- • Body mass index (BMI) greater than 50
- • Impossibility of placing the CT belt at the level of the chest skin (lesions, bandages, dressings, chest drains ...)
- • Patients with unstable spinal lesions or fractures
- • Allergy to tomography belt materials: silicone, brass, stainless steel
- • Pacemaker, implantable cardiac defibrillator and other pacemakers
- • 7. Patients under legal protection (tutorship / guardianship)
About Bioserenity
Bioserenity is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative technology and data-driven solutions. With a focus on developing wearable medical devices and software for the remote monitoring of chronic conditions, Bioserenity aims to enhance patient care and streamline clinical research processes. The company leverages its expertise in digital health to facilitate real-time data collection and analysis, improving the efficiency and efficacy of clinical trials. By prioritizing patient experience and engagement, Bioserenity is committed to transforming the landscape of clinical research and contributing to the development of effective therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials